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New perspectives in the 
diagnosis of pediatric male 
hypogonadism: the importance 
of AMH as a Sertoli cell marker
Novas perspectivas no diagnóstico do hipogonadismo pediátrico 
masculino: a importância do AMH como marcador de células de Sertoli
Romina P. Grinspon1, Rodolfo A. Rey1,2
SUMMARY
Sertoli cells are the most active cell population in the testis during infancy and childhood. In these 
periods of life, hypogonadism can only be evidenced without stimulation tests, if Sertoli cell function 
is assessed. AMH is a useful marker of prepubertal Sertoli cell activity and number. Serum AMH is 
high from fetal life until mid-puberty. Testicular AMH production increases in response to FSH and is 
potently inhibited by androgens. Serum AMH is undetectable in anorchidic patients. In primary or cen-
tral hypogonadism affecting the whole gonad and established in fetal life or childhood, serum AMH 
is low. Conversely, when hypogonadism affects only Leydig cells (e.g. LHb mutations, LH/CG receptor 
or steroidogenic enzyme defects), serum AMH is normal or high. In pubertal males with central hy-
pogonadism, AMH is low for Tanner stage (reflecting lack of FSH stimulus), but high for the age (indi-
cating lack of testosterone inhibitory effect). Treatment with FSH provokes an increase in serum AMH, 
whereas hCG administration increases testosterone levels, which downregulate AMH. In conclusion, 
assessment of serum AMH is helpful to evaluate gonadal function, without the need for stimulation 
tests, and guides etiological diagnosis of pediatric male hypogonadism. Furthermore, serum AMH is 
an excellent marker of FSH and androgen action on the testis. Arq Bras Endocrinol Metab. 2011;55(8):512-9
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SUMáRio
As células de Sertoli são a população de células mais ativa nos testículos durante a primeira e 
segunda infância. Neste período, o hipogonadismo só pode ser evidenciado sem o uso de testes 
estimulatórios se a função das células de Sertoli for avaliada. O AMH é um marcador útil do nú-
mero e da atividade das células de Sertoli no período pré-puberal. A concentração sérica de AMH 
é alta da metade da vida fetal até a metade da puberdade. A produção de AMH pelos testículos 
aumenta em resposta ao FSH e é potencialmente inibida por androgênios. O AMH sérico não é 
detectável em pacientes anorquídicos. No hipogonadismo central ou primário afetando a gônada 
inteira, ou estabelecido na vida fetal ou infância, a concentração de AMH sérica é baixa. Por outro 
lado, quando o hipogonadismo afeta apenas as células de Leydig (por exemplo, nas mutações, 
LHb, defeitos do receptor de LH/CG ou das enzimas esteroidogênicas), a concentração de AMH sé-
rico é normal ou alta. Em meninos púberes com hipogonadismo central, a concentração de AMH 
é baixa para o estágio na escala de Tanner (refletindo a falta de estímulo pelo FSH), mas alta para a 
idade (indicando a falta do efeito inibidor da testosterona). O tratamento com FSH provoca um au-
mento do AMH sérico, enquanto a administração de hCG aumenta os níveis de testosterona, que 
fazem a downregulation do AMH. Em conclusão, a concentração sérica de AMH é útil na avaliação 
da função gonadal, excluindo a necessidade de testes estimulatórios, e direciona o diagnóstico 
etiológico do hipogonadismo pediátrico masculino. Além disso, o AMH sérico é um marcador 
excelente da ação do FSH e dos androgênios nos testículos. Arq Bras Endocrinol Metab. 2011;55(8):512-9
Descritores
Hipogonadismo hipogonadotrófico; hipergonadismo hipogonadotrófico; testículos; anorquia; criptorquidismo; desordens do 
desenvolvimento sexual 
Co
py
rig
ht
©
 A
BE
&
M
 to
do
s o
s d
ire
ito
s r
es
er
va
do
s.
513Arq Bras Endocrinol Metab. 2011;55/8
Pediatric male hypogonadism
iNTRoDUCTioN
The hypothalamic-pituitary-testicular axis under-goes maturational changes that are specific to 
each of its components along fetal and postnatal life. 
The axis has classically been described to have a master 
regulator, the hypothalamic gonadotropin-releasing 
hormone (GnRH), driving pituitary gonadotropin 
(LH and FSH) secretion, which finally regulates tes-
ticular function. Two discrete, though interacting, 
compartments are present in the testes from its initial 
differentiation in early fetal life through adulthood: 
the seminiferous tubules, containing Sertoli and germ 
cells, and the interstitial tissue, containing Leydig cells. 
Sertoli cells are known to have FSH receptors, whereas 
Leydig cells have LH receptors. Assessment of gonadal 
function has typically been focused on Leydig cell an-
drogen secretion. In this review, we will address the 
relevance of anti-Müllerian hormone (AMH) as a Ser-
toli cell marker in the understanding of prepubertal 
male hypogonadism.
oNToGENY oF THE HYPoTHALAMiC-PiTUiTARY-
TESTiCULAR AXiS
Testes differentiate by the end of the 5th embryonic 
week. Sertoli and germ cells form the seminiferous 
cords. Sertoli cells secrete AMH, responsible for the re-
gression of Müllerian ducts, the anlagen of the uterus 
and Fallopian tubes. The onset of AMH secretion is in-
dependent of pituitary function. Afterwards, fetal FSH 
regulates Sertoli cell activity (1). Leydig cells located in 
the interstitial tissue secrete testosterone and insulin-
like factor 3 (INSL3) in response to placental chorionic 
gonadotropin (hCG) (2,3). Androgens are responsible, 
during the first trimester, for the differentiation of the 
Wolffian duct into the epididymis, seminal vesicle, and 
vas deferens, as well as for the masculinisation of ex-
ternal genitalia. During the third quarter, hCG levels 
decline, and LH is the main responsible for testoster-
one and INSL3 secretion. INSL3 and testosterone are 
involved in testicular descent while testosterone is also 
responsible for penile growth.
At birth, gonadotropin, testosterone and AMH 
levels are transiently low (4). They subsequently increase 
and remain high during the first 3-6 months of life (5). 
FSH stimulates Sertoli cell proliferation and AMH se-
cretion (6). Thereafter, gonadotropins decrease again, 
resulting in a fall of testicular testosterone secretion 
to very low or undetectable levels during infancy and 
childhood (Figure 1). Therefore, during childhood, a 
physiologic state of hypogonadotrophic hypoandrogen-
ism exists, compared with the fetal, neonatal and adult 
periods. However, Sertoli cells are intensely active: they 
proliferate resulting in an increase in testis size from ap-
proximately 0.5 cm3, in the first year of life, to 1.5 cm3 
at 10 years of age (Figure 2) (7,8). AMH, a conspicuous 
marker of both basal and FSH-stimulated Sertoli cell 
function, remains high during infancy and childhood 
(Figure 1). 
At the onset of puberty, the reactivation of the hy-
pothalamic-gonadotrophin axis induces the functional 
activity of Leydig cells again. Intratesticular androgen 
concentration increases before serum testosterone (9), 
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Figure 1. Schematic ontogeny of circulating levels of gonadotropins, 
testosterone (T) and anti-Müllerian hormone (AMH) in the male. Reprinted 
with permission from: Grinspon R. P. and Rey R. A. Anti-Müllerian hormone 
and Sertoli cell function in paediatric male hypogonadism. Horm Res 
Paediatr. 2010;73:81-92. Copyright S. Karger A. G., Basel, 2010.
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Figure 2. Schematic ontogeny of the evolution of testicular volume from 
birth to adulthood. Seminiferous tubules (Sertoli + germ cells) are always 
the major component of the testis. From birth and during the whole 
prepubertal period (i.e. until ages 9-14 yr, Tanner stage 1), seminiferous 
tubule volume depends mainly on Sertoli cells, whereas the significant 
increase in testicular volume during pubertal development (i.e. between 
Tanner stages 1 and 5) is mainly due to germ cell proliferation. Reprinted 
with permission from: Rey R. Regulation of spermatogenesis. Endocrine 
Development. 2003;5:38-55. Söder O (ed.): The Developing Testis. 
Physiology and Pathophysiology. Copyright S. Karger A. G., Basel, 2003.
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and provokes Sertoli cell maturation, characterized by 
arrested proliferation and downregulation of AMH 
(Figure 1) (10). Pubertal spermatogenesis is triggered 
as a result of the production of spermatozoa. Clinically, 
the onset of puberty is defined by testicular volume ≥ 
4 mL. The subsequent increase in gonadal size to a final 
volume of 15-25 mL is dependent on germ cell pro-
liferation (Figure 2), which depends on intratesticular 
androgen levels, and normal androgen receptor func-
tion in Sertoli cells. 
AMH AND SERToLi CELL PHYSioLoGY
AMH is a distinctive marker of immature Sertoli cells. 
Serum AMH is transiently low in the first weeks af-
ter birth, then increases and peaks at the age of 2-3 
years, and remains high until the onset of puberty. 
Then, AMH decreases, mainly between pubertal Tan-
ner stages 2 and 3, to reach low adult levels (Table 1) 
(11,12).
The onset of AMH expression in fetal life and the 
maintenance of its basal levels are gonadotropin-inde-
pendent (13). However, serum AMH is low in patients 
with congenital hypogonadotropic hypogonadism, and 
increases in response to exogenous FSH administration 
(14-16), indicating that serum AMH is a useful marker 
of FSH action on the prepubertal testis. Low serum 
AMH correlates with small testes (6).
Androgens are potent inhibitors of AMH produc-
tion in Sertoli cells during normal pubertal develop-
ment. The negative correlation between testosterone 
and AMH is observed also in central early puberty and 
in gonadotropin-independent early puberty (testotoxi-
cosis), suggesting that androgens are responsible for 
AMH downregulation, independent of age and gon-
adotropin levels (17). Furthermore, in patients with 
defective androgen production or sensitivity, AMH 
levels are abnormally elevated (18,19). The inhibitory 
effect of androgens prevails over the positive effect of 
FSH on AMH secretion in the pubertal testis (Figure 3). 
In the fetal and neonatal testis, high androgen levels 
are unable to downregulate AMH production owing 
to physiological androgen insensitivity of Sertoli cells in 
these periods. In fact, Sertoli cell nuclei lack androgen 
receptor expression before the age of 6 months (Figure 3) 
(16,20-22).
DEFiNiTioNS AND CLASSiFiCATioN oF MALE 
HYPoGoNADiSM
In the adult male, hypogonadism refers to testicular fai-
lure associated with androgen deficiency and/or disor-
ders in sperm production. This classical definition does 
not take into account the potential deficiencies in Ser-
toli cells. In the prepubertal male, Sertoli cells are the 
most active testicular cell population, while testostero-
ne and sperm production are physiologically inexistent. 
Therefore, male hypogonadism in the boy can only be 
discovered if Sertoli cell function is assessed.
Classification of hypogonadism (Table 2)
Hypothalamic-pituitary (central), testicular (primary), 
or combined hypogonadism
Central hypogonadism is characterised by gonadal fai-
lure owing to a central disorder affecting the hypotha-
lamic GnRH pulse generator, or pituitary gonadotroph 
LH/FSH secretion. In primary hypogonadism, prima-
ry testicular failure exists. Finally, certain disorders may 
concomitantly impair the hypothalamic-pituitary axis 
and the testis, and provoke combined hypogonadism.
Whole or dissociated testicular failure
Primary, central or combined hypogonadism may re-
flect the concomitant impairment of all testicular cell 
populations, i.e., “whole testicular failure or hypogo-
nadism”. Conversely, when only one testicular com-
partment (seminiferous tubules or interstitial tissue) is 
primarily affected, there is “dissociated testicular failure 
or hypogonadism”.
Table 1. Serum AMH in normal males, using the AMH/MIS ELISA from 
Beckman-Coulter-Immunotech. Data from reference (11)
Age group
Serum AMH 
Median (3rd-97th percentiles)
pmol/L μg/L
0-14 days 584 (253-1038) 82 (35-145)
15 days - 6 months 697 (421-1470) 98 (59-206)
6 months - 2 years 1132 (684-2329) 159 (96-326)
2 - 9 years 684 (236-1831) 96 (33-256)
9 - 18 years
G1 713 (257-1371) 100 (36-192)
G2 295 (69-1017) 41 (10-142)
G3 71 (30-423) 10 (4-59)
G4 65 (33-164) 9 (5-23)
G5 82 (38-195) 11 (5-27)
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Figure 3. Regulation of testicular AMH secretion by gonadotropins and androgens. In general, the hypothalamus regulates LH and FSH secretion of the 
gonadotroph by means of gonadotropin-releasing hormone (GnRH). LH acts on the LH receptor (LH-R) present in Leydig cells, inducing testosterone (T) 
secretion. FSH acts on the FSH receptor (FSH-R) present in Sertoli cells. The hypothalamic-pituitary-gonadal axis is active in the fetus and early infancy, is 
quiescent during childhood, and is reactivated in puberty. FSH is a moderate inducer of AMH secretion, whereas T, acting by means of the androgen receptor 
(AR), is a potent inhibitor of AMH production. In the normal fetus and infant, as well as in patients with androgen insensitivity syndrome (AIS), the lack of AR 
expression results in high AMH production by Sertoli cells (I). During childhood, there is a physiologic hypogonadotrophic state resulting in very low T; AMH 
levels remain high, but somewhat lower, probably due to the lack of FSH stimulus (II). In normal or early puberty, T prevails over FSH, resulting in AMH inhibition 
(III). In congenital central hypogonadism, AMH is lower than in the normal boy because of the longstanding lack of FSH from fetal life; however, at pubertal age, 
the inhibitory effect of T is also absent, and AMH remains higher than in normal puberty (IV). In Leydig cell-specific primary hypogonadism (Leydig cell aplasia 
or hypoplasia due to LH-R defects, or in defects of steroidogenesis), the inhibitory effect of androgens is absent, and AMH levels are high. The orange area 
represents the testis. Thickness of lines is correlated with hormone effect on its target. Reprinted with permission from: Grinspon R. P. and Rey R. A. Anti-
Müllerian hormone and Sertoli cell function in paediatric male hypogonadism. Horm Res Paediatr. 2010;73:81-92. Copyright S. Karger A. G., Basel, 2010.
Table 2. Classification of hypogonadism 
Central hypogonadism
Whole gonadal dysfunction Cell-specific gonadal dysfunction
Fetal-onset (2nd - 3rd quarters) Isolated hypogonadotropic hypogonadism (IHH)
Multiple pituitary-hormone-deficiency
Leydig cells: LHb-subunit gene mutation
Sertoli cells: FSHb-subunit gene mutation
Childhood-onset Endocrine disorders: hypothyroidism, hyperprolactinemia
Central Nervous System tumours, Langerhan’s hystiocytosis
None
Peri-pubertal Functional central hypogonadism: anorexia nervosa
Endocrine disorders: hypothyroidism, hyperprolactinemia
Central Nervous System tumours, Langerhan’s hystiocytosis
None
 
 
Primary hypogonadism
Whole gonadal dysfunction Cell-specific gonadal dysfunction
Fetal-onset (1st quarter) Gonadal dysgenesis Leydig cell aplasia/hypoplasia
Steroidogenic protein defects
Sertoli cell: PMDS due to AMH mutation
Fetal-onset (2nd - 3rd quarters) Endocrine disruptors
Testicular regression syndrome
Testicular torsion
Sertoli cell: FSH-R mutation
Childhood-onset Cryptorchidism
Testicular torsion
Orchitis
Chemotherapy/Radiotherapy
Trisomy 21
None
Peri-pubertal Cryptorchidism
Testicular torsion
Orchitis
Chemotherapy/Radiotherapy
Klinefelter syndrome
Germ cells: XX male
 
 
Combined hypogonadism
Whole gonadal dysfunction Cell-specific gonadal dysfunction
Fetal-onset (1st quarter) DAX1 gene mutations None
Fetal-onset (2nd - 3rd quarter) Prader-Willi syndrome None
Childhood-onset Total body irradiation None
Peri-pubertal Total body irradiation None
GnRH
L
T
FSH-R
AMH AMH AMHAM AM
FSH-RA A A AFSH-R FSH-R FSH-R
T T T
L
LH- LH- LH- LH- LH-
L L LFS FS FS FS FS
GnRH GnRH GnRH GnRH
Fetal – 0-6 months
AIS (puberty)
Childhood Normal Puberty
Early Puberty
Central
Hypogonadism
Leydig cell aplasia
T synthesis 
Gonadotroph
Leydig cell
Sertoli cell
I II III IV V
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Fetal-, childhood-, pubertal-onset hypogonadism
Male hypogonadism yields different clinical consequen-
ces depending on the period of life in which it is esta-
blished. Fetal-onset hypogonadism, established early in 
the 1st quarter, results in disorders of sex development, 
with ambiguous or female genitalia due to insufficient 
testis hormone levels during the critical window of male 
sex differentiation. Gonadal dysgenesis is an example of 
whole gonadal dysfunction, whereas Leydig cell apla-
sia/hypoplasia and steroidogenic defects are dissociated 
forms of hypogonadism. Central hypogonadism cannot 
result in genital ambiguity, since Leydig cell function 
in the 1st quarter of fetal life is dependent on placental 
hCG. Fetal hypogonadism (primary, central or combi-
ned) of the 2nd half of gestation typically results in mi-
cropenis and cryptorchidism. When established during 
infancy or childhood, hypogonadism may remain un-
diagnosed until the age of puberty – unless Sertoli cell 
function is assessed. At pubertal age, hypogonadism 
can provoke lack or arrest of pubertal development. 
PEDiATRiC MALE HYPoGoNADiSM: USEFULNESS 
oF AMH LEVELS
The evaluation of basal testicular function in infancy 
and childhood relies mainly on the assessment of Ser-
toli cell markers, since gonadotropin and testosterone 
levels normally decrease to very low values until the on-
set of puberty (23-26). Serum AMH reliably reflects 
the presence and function of testes in prepubertal boys, 
without the need for any stimulation test (24,27,28). 
To evaluate gonadotrophs or Leydig cell function, dy-
namic tests are necessary.
Central hypogonadism with “whole testicular 
dysfunction”
isolated hypogonadotropic hypogonadism and 
multiple pituitary hormone deficiency
Serum AMH levels are low in infants with congenital 
central hypogonadism. Early treatment with FSH results 
in testicular growth – owing to Sertoli cell proliferation 
– and serum AMH elevation (14). In untreated 
patients of pubertal age, serum AMH is elevated for 
age (because serum testosterone remains at prepubertal 
levels and does not downregulate AMH), but lower 
than expected for patient’s Tanner stage and serum 
testosterone (15,29), which reflects the lack of FSH 
stimulus (Figure 3). FSH treatment provokes an 
increase in serum AMH. Further treatment with hCG 
results in an elevation of intratesticular androgen 
levels, which inhibit AMH (Figure 4). Conversely, 
downregulation of AMH is less significant when 
patients receive exogenous testosterone, probably due 
to the lower intratesticular androgen levels obtained 
with this treatment (15). AMH and inhibin B are 
normal in boys with constitutional delay of puberty, 
reflecting the eugonadal state in these patients (30,31).
Figure 4. Effect of recombinant human FSH (rhFSH) and hCG treatment on 
testicular anti-Müllerian hormone (AMH) production by the testis in 
patients with previously untreated central hypogonadism. Initial treatment 
with rhFSH during 30 days resulted in an elevation of serum AMH in all 8 
patients, while testosterone (T) remained at prepubertal levels. Shaded area 
represents normal AMH for Tanner I stage, according to T levels observed 
in these patients. Subsequent addition of hCG treatment resulted in 
elevation of T, which provoked a decline in serum AMH. Shaded area 
represents AMH values for Tanner IV-V stages, according to T levels 
observed in treated patients. Reprinted with permission from: Grinspon R. 
P. and Rey R. A. Anti-Müllerian hormone and Sertoli cell function in 
paediatric male hypogonadism. Horm Res Paediatr. 2010;73:81-92. 
Copyright S. Karger A. G., Basel, 2010.
Central hypogonadism with “dissociated testicular 
dysfunction”
Central hypogonadism with Leydig cell-specific 
dysfunction
Isolated LH deficiency, due to mutations of the LHb-
subunit gene, results in failure of Leydig cell differen-
tiation and testosterone secretion in late fetal life and 
pubertal age (32). In mice, FSH levels are usually ele-
vated and Sertoli cells remain immature, producing 
high AMH levels (33).
Patients with congenital central hypogonadism
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Primary hypogonadism with “whole testicular 
dysfunction”
Gonadal dysgenesis, vanishing testes and anorchia
Gonadal dysgenesis established in the first quarter 
of fetal life results in female or ambiguous genitalia, 
reflecting the degree of testicular hormone deficiency. 
Vanishing or regression of testicular tissue occurring in 
the second half of fetal life does not preclude virilisation, 
but micropenis and hypoplastic scrotum occur. In all 
cases, serum AMH is low or undetectable, according to 
the amount of testicular tissue remaining (19,27,28). 
In boys with isolated hypospadias but normal pe-
nis size and scrotum and descended testes, AMH and 
testosterone are normal, indicating that there is no tes-
ticular dysfunction (34).
Klinefelter syndrome is a sex-chromosome aneu-
ploidy characterised by late-onset testicular dysgenesis. 
AMH levels are normal until pubertal Tanner stage 3, in 
correlation with normal inhibin B and FSH. Thereafter, 
Sertoli cell function deteriorates progressively, resulting 
in extremely low or undetectable AMH, together with 
undetectable inhibin B, very high FSH levels and small 
testis volume (35). Another aneuploidy with primary 
hypogonadism is trisomy 21; however, both the tubu-
lar and interstitial compartments are affected in a high 
proportion of these patients from early infancy. Serum 
AMH is low and testosterone reaches low/normal 
levels but with high LH (11).
Cryptorchidism
Rather than a pathology, cryptorchidism is a clinical 
a sign with many possible etiologies. It may reflect a 
primary hypogonadal disorder with “whole testicular 
dysfunction”, result from hypogonadotropic hypog-
onadism, or from rare mutations of INSL3 or its recep-
tor (3), or even from anatomical defects of the inguinal 
region or abdominal wall (i.e., not associated with hy-
pogonadism). According to its etiology, cryptorchidism 
may be associated with normal or impaired Sertoli cell 
function. In boys with bilateral cryptorchidism, AMH 
is low in approximately 75% of those with nonpalpable 
gonads and 35% of those with inguinal gonads, indicat-
ing Sertoli cell dysfunction (36). AMH is expected to 
be normal in infants with abdominal wall or inguinal 
region defects, or with impaired INSL3 signalling. As 
previously discussed, AMH levels are low in patients 
with hypogonadotropic hypogonadism (14,15,29).
Chemotherapy/Radiotherapy
Chemotherapy and radiotherapy affect primarily germ 
cells (37). No studies have reported AMH values in 
these cases.
Primary hypogonadism with “dissociated testicular 
dysfunction”
Primary hypogonadism with Sertoli cell-specific 
dysfunction
FSH receptor mutations result in reduced Sertoli cell 
number and function, leading to small testis size, low 
inhibin B and moderately elevated FSH (38). Low 
AMH could be expected, but no reports exist. Because 
basal AMH secretion in early fetal life is FSH-indepen-
dent, Müllerian ducts normally regress in these patients.
AMH gene mutations are responsible for the AMH-
negative form of the Persistent Müllerian Duct Syn-
drome (PMDS), characterized by undetectable serum 
AMH. A distinction should be made from the AMH-
positive form of PMDS due to AMH receptor muta-
tions, where serum AMH is normal, indicating a eugo-
nadal state [reviewed in ref. (39)].
Primary hypogonadism with Leydig cell-specific 
dysfunction
Inactivating mutations of the LH/CG receptor or 
steroi dogenic enzymes in 46,XY individuals result in 
isolated hypoandrogenism leading to the development 
of female or ambiguous external genitalia. It is possible 
to distinguish these types of disorders of sex differen-
tiation with those resulting from testicular dysgenesis 
(i.e. whole gonadal dysfunction) because serum AMH 
is normal/high owing to the lack of androgen inhibi-
tory effect (Figure 3) (19).
Primary hypogonadism with germ cell-specific 
dysfunction
In XX males, AMH and testosterone are normal, in-
dicating that the somatic cells of the gonads are not 
primarily affected (19). However, germ cells fail to pro-
gress to gametogenesis, and enter apoptosis in puberty.
AMH levels have not been evaluated in other disor-
ders where germ cells are the primarily affected popula-
tion, like DAZ (Deleted in Azoospermia) microdele-
tions of the Y chromosome.
Combined hypogonadism (central and primary) 
with “whole testicular dysfunction”.
Pediatric male hypogonadism
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DAX1 is expressed at several levels of the hypotha-
lamic-pituitary-gonadal and adrenal axes (40). DAX1 
gene mutations cause an X-linked disorder character-
ized by congenital adrenal hypoplasia, and hypotha-
lamic-pituitary hypogonadism combined with testicular 
origin. There is a primary testicular defect (41) associ-
ated with a lack of gonadotropin elevation, due to im-
paired functional capacity of the pituitary. Both Serum 
AMH and inhibin B are low since early pubertal stages, 
indicating the existence of a primary failure of testicular 
function (42).
Prader-Willi syndrome is another form of combined 
central and peripheral hypogonadism. Boys and adoles-
cents present normal/low AMH, low inhibin B, nor-
mal/low testosterone and normal/high FSH and LH 
(43-45). 
CoNCLUDiNG REMARKS
The diagnosis of hypogonadism may be missed in in-
fancy and childhood if attention is driven only to go-
nadotropins and testosterone. Sertoli cells are the main 
active population during prepubertal ages. Small tes-
tes are indicative of reduced number of Sertoli cells, 
either primary or secondary to FSH deficiency. Sertoli 
cell markers, like serum AMH and inhibin B, are most 
helpful in the evaluation of gonadal function, without 
the need for stimulation tests, and guide the etiological 
diagnosis of male hypogonadism in pediatric patients. 
Serum AMH is an excellent marker of FSH and andro-
gen action in the testis.
Disclosure: Rodolfo A. Rey has received royalties from Beckman-
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